Behbahani Ali 4

What Happened

• Behbahani Ali, a 10% owner and Outside Director of SpyGlass Pharma (SGP), received an award of 27,400 shares on February 5, 2026. The award was reported as acquired at $0 (no cash paid) and is coded as a derivative/grant (transaction type A).
• This was a grant of equity subject to vesting rather than an open-market purchase or sale; the filing shows no immediate sale or cash exercise.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely filing).
• Transaction type: Award/Grant (derivative), 27,400 shares, acquisition price $0.00 (no cash paid).
• Vesting: Footnote—shares vest 1/36th each month following the February 5, 2026 grant date, conditioned on the Reporting Person continuing as an Outside Director under the Issuer’s 2026 Equity Incentive Plan.
• Shares owned after transaction: Not specified in the provided filing details.
• Transaction code: A (grant/award). No 10b5-1 plan, tax withholding, or disposition noted in the filing.

Context

• This is an equity award to an outside director and a 10% owner, not a market trade. Awards like this are common for board compensation and align the director’s interests with shareholders but do not by themselves indicate immediate buying or selling intent.
• Because the award vests monthly over 36 months and was granted at $0, the recipient will only receive vested shares over time if service continues.